CytomX Therapeutics (NASDAQ:CTMX) Receives "Neutral" Rating from HC Wainwright

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report)'s stock had its "neutral" rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports.

CytomX Therapeutics Stock Down 10.5 %

CytomX Therapeutics stock traded down $0.12 during trading hours on Tuesday, hitting $1.02. The stock had a trading volume of 1,974,941 shares, compared to its average volume of 1,145,109. The stock has a market capitalization of $79.82 million, a P/E ratio of 6.00 and a beta of 1.03. CytomX Therapeutics has a 12-month low of $0.83 and a 12-month high of $5.85. The stock's 50-day moving average price is $1.06 and its 200-day moving average price is $1.17.

CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.23. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. The firm had revenue of $33.43 million during the quarter, compared to analysts' expectations of $18.92 million. During the same period in the previous year, the company earned $0.04 earnings per share. On average, research analysts expect that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. FMR LLC grew its position in CytomX Therapeutics by 17.3% during the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company's stock valued at $335,000 after buying an additional 41,949 shares during the period. Candriam S.C.A. bought a new stake in CytomX Therapeutics during the second quarter valued at approximately $256,000. Cubist Systematic Strategies LLC grew its position in CytomX Therapeutics by 96.6% during the second quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company's stock valued at $100,000 after buying an additional 40,309 shares during the period. Acadian Asset Management LLC grew its position in CytomX Therapeutics by 1.4% during the second quarter. Acadian Asset Management LLC now owns 2,728,569 shares of the biotechnology company's stock valued at $3,324,000 after buying an additional 37,739 shares during the period. Finally, XTX Topco Ltd grew its position in CytomX Therapeutics by 382.6% during the second quarter. XTX Topco Ltd now owns 60,586 shares of the biotechnology company's stock valued at $74,000 after buying an additional 48,033 shares during the period. 67.77% of the stock is owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.